AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37586882 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-ProS predicting motor decline in PD.
Number of subjects: 420
Study 37586906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular fat fraction (IMFF) ≥ 15%
Number of subjects: 116
Study 37586906 — intervention group
Group type: EXPERIMENTAL
Intervention: Significant weight loss
Number of subjects: 116
Study 37587149 — intervention group
Group type: EXPERIMENTAL
Intervention: cetuximab-800CW
Number of subjects: 65
Study 37587183 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplatzer Piccolo™ Occluder
Number of subjects: 200
Study 37587184 — intervention group
Group type: EXPERIMENTAL
Intervention: IV caffeine 20 mg/kg followed by up to two daily doses of 5 mg/kg
Number of subjects: 17
Study 37587184 — intervention group
Group type: EXPERIMENTAL
Intervention: IV caffeine 20 mg/kg followed by up to two daily doses of 10 mg/kg
Number of subjects: 17
Study 37587184 — intervention group
Group type: EXPERIMENTAL
Intervention: IV caffeine (both dosages)
Number of subjects: 17
Study 37587184 — intervention group
Group type: COMPARATOR
Intervention: Whole-Body Hypothermia for HIE trial
Number of subjects: 17
Study 37587323 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV cure (DAAs treatment)
Number of subjects: 2740
Study 37587323 — intervention group
Group type: COMPARATOR
Intervention: Current or past unhealthy alcohol use
Number of subjects: 2740
Study 37587323 — intervention group
Group type: COMPARATOR
Intervention: Living in poverty
Number of subjects: 2740
Study 37587323 — intervention group
Group type: COMPARATOR
Intervention: Severe liver fibrosis
Number of subjects: 2740
Study 37587323 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 2740
Study 37587489 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based walking intervention combined with face-to-face sessions and regular telephone contact
Number of subjects: 202
Study 37587489 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 202
Study 37587493 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab at Weeks 0, 4, then every 8 weeks (Q8W)
Number of subjects: 0
Study 37587493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37587493 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 0
Study 37587492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous arginine therapy (200 mg/kg loading dose, max 20 g; followed by 100 mg/kg three times a day, max 10 g)
Number of subjects: 360
Study 37587492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline loading dose followed by normal saline three times a day)
Number of subjects: 360
Study 37587492 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous arginine therapy
Number of subjects: 360
Study 37587502 — intervention group
Group type: EXPERIMENTAL
Intervention: FLYSYN (Fc-optimized antibody directed to FLT3/CD135), administered intravenously at different dose levels (0.5 mg/m² in cohort 1-5)
Number of subjects: 31
Study 37587502 — intervention group
Group type: EXPERIMENTAL
Intervention: FLYSYN (Fc-optimized antibody directed to FLT3/CD135)
Number of subjects: 31
Study 37587516 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired RV GLS (> -15.4%)
Number of subjects: 659
Study 37587516 — intervention group
Group type: EXPERIMENTAL
Intervention: RV GLS
Number of subjects: 659
Study 37587517 — intervention group
Group type: EXPERIMENTAL
Intervention: High-touch implementation support (facilitation and tailored technical assistance)
Number of subjects: 24
Study 37587517 — intervention group
Group type: COMPARATOR
Intervention: Standard low-touch implementation support (based on Replicating Effective Programs)
Number of subjects: 24
Study 37587517 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers FIRST participation
Number of subjects: 24
Study 37587552 — intervention group
Group type: EXPERIMENTAL
Intervention: electronically delivered Cognitive Behavioral Therapy (e-CBT) program
Number of subjects: 100
Study 37587552 — intervention group
Group type: COMPARATOR
Intervention: web-based mental health check-in program
Number of subjects: 100
Study 37587580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 7119
Study 37587580 — intervention group
Group type: COMPARATOR
Intervention: Dual antiplatelet therapy (DAPT) with aspirin and ticagrelor
Number of subjects: 7119
Study 37587591 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose colchicine (0.6 mg daily) with ticagrelor or prasugrel
Number of subjects: 200
Study 37587595 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-AKI risk score model 1
Number of subjects: 8201
Study 37587595 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-AKI risk score model 2
Number of subjects: 8201
Study 37587595 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-AKI patients
Number of subjects: 8201
Study 37587606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker Implantation after TAVR
Number of subjects: 0
Study 37587734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective supraclavicular nerve block with 0.1 mL/kg of 0.5% ropivacaine (SSCNB group)
Number of subjects: 50
Study 37587734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 50
Study 37587734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective supraclavicular nerve block
Number of subjects: 50
Study 37587845 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 805
Study 37588049 — intervention group
Group type: EXPERIMENTAL
Intervention: Kombucha tea
Number of subjects: 0
Study 37588173 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspired oxygen fraction of 0.8 (hyperoxia)
Number of subjects: 0
Study 37588173 — intervention group
Group type: COMPARATOR
Intervention: Inspired oxygen fraction of 0.3 (normoxaemia)
Number of subjects: 0
Study 37588266 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted dosing of fibrinogen concentrate
Number of subjects: 0
Study 37588266 — intervention group
Group type: COMPARATOR
Intervention: Empiric dosing of fibrinogen concentrate
Number of subjects: 0
Study 37588271 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IL-8 on postoperative day 1
Number of subjects: 0
Study 37588271 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IL-10
Number of subjects: 0
Study 37588271 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium
Number of subjects: 0
Study 37588575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine sedation
Number of subjects: 5
Study 37588584 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with propofol and alfentanil
Number of subjects: 40
Study 37588582 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital postoperative complications of any cause
Number of subjects: 0
Study 37588582 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital all-cause mortality
Number of subjects: 0
Study 37588582 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hospital stay after surgery
Number of subjects: 0
Study 37588582 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission to a critical care unit within 30 days after surgery during the index hospitalisation
Number of subjects: 0
Study 37588667 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily electronically recorded patient-reported outcomes (ePROs) on the presence of MG symptoms, level of symptom severity (MG-ADL), and exacerbation status.
Number of subjects: 113
Study 37588667 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported MG-ADL scores during exacerbation periods.
Number of subjects: 113
Study 37588667 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported MG-ADL scores during non-exacerbation periods.
Number of subjects: 113
Study 37588667 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic changes in day-to-day symptom reporting and severity, daily step counts, clinical characteristics.
Number of subjects: 113
Study 37588667 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupervised machine learning methods applied to symptom data.
Number of subjects: 113
Study 37588691 — intervention group
Group type: EXPERIMENTAL
Intervention: Altered cerebral autoregulation
Number of subjects: 36
Study 37588691 — intervention group
Group type: COMPARATOR
Intervention: Preserved cerebral autoregulation
Number of subjects: 36
Study 37588731 — intervention group
Group type: EXPERIMENTAL
Intervention: IORT boost with low kV X-rays
Number of subjects: 73
Study 37588783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvres in the prone position
Number of subjects: 30
Study 37588787 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower oxygenation target (8 kPa)
Number of subjects: 168
Study 37588787 — intervention group
Group type: COMPARATOR
Intervention: Higher oxygenation target (12 kPa)
Number of subjects: 168
Study 37588789 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 37588789 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 0
Study 37588789 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 0
Study 37589154 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP intervention (<120 mm Hg)
Number of subjects: 7939
Study 37589154 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP intervention (<140 mm Hg)
Number of subjects: 7939
Study 37589161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemoradiation (CCRT)
Number of subjects: 48
Study 37589161 — intervention group
Group type: COMPARATOR
Intervention: Radiation alone
Number of subjects: 48
Study 37589219 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Number of subjects: 994
Study 37589219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994
Study 37589315 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ICU stroke
Number of subjects: 3144
Study 37589315 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ICU depression
Number of subjects: 3144
Study 37589506 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFR2 small interfering RNA
Number of subjects: 0
Study 37589506 — intervention group
Group type: COMPARATOR
Intervention: Negative control treatment
Number of subjects: 0
Study 37589641 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphase SCS therapy A (approximately 600-1500 Hz)
Number of subjects: 122
Study 37589641 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphase SCS therapy B (approximately 300-600 Hz)
Number of subjects: 122
Study 37589641 — intervention group
Group type: COMPARATOR
Intervention: Commercial SCS therapy
Number of subjects: 122
Study 37589641 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphase SCS
Number of subjects: 122
Study 37589641 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-related adverse events
Number of subjects: 122
Study 37589639 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous IFNγ-stimulated MSC(M) injection into submandibular gland
Number of subjects: 6
Study 37589639 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous IFNγ-stimulated MSC(M) injection
Number of subjects: 6
Study 37589639 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life surveys
Number of subjects: 6
Study 37589719 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 76
Study 37589719 — intervention group
Group type: COMPARATOR
Intervention: Controls with overweight/obesity (CWO)
Number of subjects: 76
Study 37589719 — intervention group
Group type: COMPARATOR
Intervention: Controls with overweight/obesity (CWO) and Type 2 diabetes (T2D)
Number of subjects: 76
Study 37589748 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) therapy
Number of subjects: 31
Study 37589748 — intervention group
Group type: EXPERIMENTAL
Intervention: MAD therapy
Number of subjects: 31
Study 37589906 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting break
Number of subjects: 45
Study 37589906 — intervention group
Group type: COMPARATOR
Intervention: No reporting break
Number of subjects: 45
Study 37589932 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL + DQS therapy
Number of subjects: 66
Study 37589932 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL therapy
Number of subjects: 66
Study 37589932 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 66
Study 37589975 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) intervention
Number of subjects: 95
Study 37589975 — intervention group
Group type: COMPARATOR
Intervention: Standard educational packet (Control)
Number of subjects: 95
Study 37589978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean nutrition intervention (access to supermarket discounts, free samples of Mediterranean diet foods, online nutrition education, email reminders, family and peer support, chef demonstrations)
Number of subjects: 485
Study 37589978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean nutrition intervention
Number of subjects: 485
Study 37589978 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diet)
Number of subjects: 485
Study 37590001 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticancer agents targeting AMPK
Number of subjects: 0
Study 37590002 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (AT)
Number of subjects: 386
Study 37590002 — intervention group
Group type: COMPARATOR
Intervention: Watchful Waiting with Supportive Care (WWSC)
Number of subjects: 386
Study 37590017 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37590203 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vibrating mesh nebuliser
Number of subjects: 60
Study 37590203 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent vibrating mesh nebuliser
Number of subjects: 60
Study 37590203 — intervention group
Group type: COMPARATOR
Intervention: Intermittent jet nebuliser
Number of subjects: 60
Study 37590267 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography (CCTA) performed once at the beginning of the study.
Number of subjects: 80
Study 37590267 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography with GLS assessment performed every three months during follow-up.
Number of subjects: 80
Study 37590267 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of new biomarkers of atherosclerosis (IL-6, MPO, TNF-alpha) every 6 months.
Number of subjects: 80
Study 37590355 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37591034 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone quartile 1
Number of subjects: 5535
Study 37591034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrone quartile 1
Number of subjects: 5535
Study 37591034 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone quartile 1 (expanded definition)
Number of subjects: 5535
Study 37591034 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrone quartile 1 (expanded definition)
Number of subjects: 5535
Study 37591034 — intervention group
Group type: EXPERIMENTAL
Intervention: Low DHEA (expanded definition)
Number of subjects: 5535
Study 37591042 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Promoting Positive Emotions (FPPE)
Number of subjects: 74
Study 37591042 — intervention group
Group type: COMPARATOR
Intervention: Written Information (WI)
Number of subjects: 74
Study 37591292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefecon (targeted-release formulation of budesonide)
Number of subjects: 364
Study 37591292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 37591293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks for up to 108 weeks
Number of subjects: 712
Study 37591293 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice)
Number of subjects: 712
Study 37591293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab plus chemotherapy (as second-line therapy)
Number of subjects: 712
Study 37591293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemiplimab 350 mg every 3 weeks
Number of subjects: 712
Study 37591308 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional clinical trials for Becker muscular dystrophy
Number of subjects: 0
Study 37591308 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural history studies
Number of subjects: 0
Study 37591308 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment concepts converting DMD to BMD phenotype
Number of subjects: 0
Study 37591308 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative efforts to improve trial readiness
Number of subjects: 0
Study 37591308 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad spectrum of disease severity
Number of subjects: 0
Study 37591454 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 new VAD item banks/measures developed: 6-item VAD Team Communication
Number of subjects: 620
Study 37591454 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item Self-efficacy Regarding VAD Self-care
Number of subjects: 620
Study 37591454 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-item Being Bothered by VAD Self-care and Limitations
Number of subjects: 620
Study 37591454 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-item Satisfaction with Treatment
Number of subjects: 620
Study 37591454 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-item Stigma
Number of subjects: 620
Study 37591454 — intervention group
Group type: EXPERIMENTAL
Intervention: All measures except VAD Team Communication
Number of subjects: 620
Study 37591480 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Veterans with a mental health diagnosis (n = 175)
Number of subjects: 380
Study 37591480 — intervention group
Group type: COMPARATOR
Intervention: Black Veterans without a mental health diagnosis (n = 205)
Number of subjects: 380
Study 37591480 — intervention group
Group type: EXPERIMENTAL
Intervention: Racialized discrimination in health care
Number of subjects: 380
Study 37591480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain self-efficacy
Number of subjects: 380
Study 37591480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related fear avoidance beliefs
Number of subjects: 380
Study 37591523 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic anticoagulants
Number of subjects: 1777
Study 37591523 — intervention group
Group type: COMPARATOR
Intervention: Higher-dose apixaban
Number of subjects: 1777
Study 37591523 — intervention group
Group type: COMPARATOR
Intervention: Apixaban
Number of subjects: 1777
Study 37591633 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (280 mg single dose)
Number of subjects: 199
Study 37591633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 37591642 — intervention group
Group type: EXPERIMENTAL
Intervention: TruST-support intervention
Number of subjects: 82
Study 37591642 — intervention group
Group type: COMPARATOR
Intervention: Static trunk support intervention
Number of subjects: 82
Study 37591648 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 4500
Study 37591648 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographics and outcomes of hospitalised patients with COVID-19
Number of subjects: 4500
Study 37591648 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-level oxygen production and support
Number of subjects: 4500
Study 37591648 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory support transitions
Number of subjects: 4500
Study 37591648 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier models
Number of subjects: 4500
Study 37591648 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistate model
Number of subjects: 4500
Study 37591655 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2% sodium bicarbonate infusion to target a plasma pH ≥ 7.30
Number of subjects: 0
Study 37591655 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium bicarbonate infusion)
Number of subjects: 0
Study 37591655 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2% sodium bicarbonate infusion
Number of subjects: 0
Study 37591656 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole-stimulated protocol
Number of subjects: 1078
Study 37591656 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement treatment (HRT)
Number of subjects: 1078
Study 37592020 — intervention group
Group type: EXPERIMENTAL
Intervention: WRAPSODY™ Cell-Impermeable Endoprosthesis
Number of subjects: 500
Study 37592059 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal metabolomic profile during pregnancy (1st, 2nd, 3rd trimester)
Number of subjects: 572
Study 37592059 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal metabolomic profile during pregnancy (2nd trimester)
Number of subjects: 572
Study 37592059 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal metabolomic profile during pregnancy (3rd trimester)
Number of subjects: 572
Study 37592059 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood metabolomic profile
Number of subjects: 572
Study 37592059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending early growth
Number of subjects: 572
Study 37592092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg QD (step-in dosing)
Number of subjects: 0
Study 37592092 — intervention group
Group type: COMPARATOR
Intervention: Bosutinib 400 mg QD (approved first-line dose)
Number of subjects: 0
Study 37592092 — intervention group
Group type: COMPARATOR
Intervention: Bosutinib 500 mg QD (approved later-line dose)
Number of subjects: 0
Study 37592104 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ipilimumab and nivolumab
Number of subjects: 92
Study 37592104 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab alone
Number of subjects: 92
Study 37592104 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in intratumoral CD8 T cell density
Number of subjects: 92
Study 37592106 — intervention group
Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel)
Number of subjects: 62
Study 37592153 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert panel grading of developmental milestones using home video recordings
Number of subjects: 5
Study 37592166 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV > 9.5%
Number of subjects: 189